Letter to editor regarding a review of MF59-adjuvanted influenza vaccine by Gärtner et al

Affiliations

• ¹ Global Medical Affairs, Sanofi, Singapore; The University of Sydney, NSW, Australia. Electronic address: Kevin.Yin@sanofi.com.
• ² Global Medical Evidence Generation, Sanofi, Singapore; London School of Hygiene and Tropical Medicine, London, UK.
• ³ Global Medical Evidence Generation, Sanofi, Swiftwater, PA, USA.
• ⁴ Global Medical Affairs, Sanofi, Lyon, France; University of Toronto, Toronto, Ontario, Canada.
• ⁵ Global Medical Affairs, Sanofi, Lyon, France.